3617 |
CAS Should Replace CEA in Patients Eligible for Bypass Surgery with Multilevel Atherosclerosis |
Piotr Odrowaz-Pieniazek |
Apr. 21. 16 |
3616 |
Balloon Expandable System |
Alan C. Yeung |
Apr. 21. 16 |
3615 |
Does Carotid Stent Cell Design Matter?: Open vs. Closed vs. Micromesh |
Mark W. Burket |
Apr. 21. 16 |
3614 |
TAVR for Bicuspid AS |
Raj Makkar |
Apr. 21. 16 |
3613 |
Tailored Carotid Protection: Matching the Device to the Patient |
Jae-Hwan Lee |
Apr. 21. 16 |
3612 |
Selection of Device and Size: Based on MDCT Assessment |
Sung Han Yoon |
Apr. 21. 16 |
3611 |
Turn to Starting Line - Which Strategy for Whom?: CAS vs. CEA vs. Medical Therapy |
Robert Bersin |
Apr. 21. 16 |
3610 |
Predictor and Prevention of Vascular Complications |
Michael Kang-Yin Lee |
Apr. 21. 16 |
3609 |
A Novel Sirolimus Drug Coated Balloon Technology |
Robert Bersin |
Apr. 21. 16 |
3608 |
BRS Failure: Insights from Imagings |
Yoshinobu Onuma |
Apr. 21. 16 |